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Abstract
The effects of methoxy-substitution at the 1-, 2-, 3- and 4-positions of 9-aminomethyl-9,10-
dihydroanthracene (AMDA) on h5-HT2A receptor affinity were determined. Racemic mixtures of
these compounds were found to show the following affinity trend: 3-MeO > 4-MeO > 1-MeO ~ 2-
MeO. Comparison of the effects of these substitutions, with the aid of computational molecular
modeling techniques, suggest that the various positional and stereochemical isomers of the
methoxy-substituted AMDA compounds interact differently with the h5-HT2A receptor. It is
predicted that for the compounds with higher affinities, the methoxy oxygen atom is able to
interact with hydrogen bond-donating sidechains within alternative h5-HT2A receptor binding
sites, whereas the lower-affinity isomers lack this ability.
The chemical features that are responsible for the potency and efficacy of agents that bind to
5-HT2A receptors, as well as the receptor-ligand interactions responsible for the ligands’
observed affinities, have not yet been fully elucidated. Toward that end, we have
synthesized and assayed many analogs1 of the selective2 5-HT2A antagonist3 9-
aminomethyl-9,10-dihydroanthracene (AMDA, 1). This work in particular builds upon
earlier studies1 of AMDA analogs in which it was shown that substituents of widely varying
size and polarity may be placed at the 3-position without a large decrease in 5-HT2A affinity.
In order to more completely determine the extent of this apparent steric and/or electrostatic
tolerance, and in particular to find AMDA analogs that have a significantly reduced affinity
for the 5-HT2A receptor, a series of AMDA analogs that are substituted at varying positions
around the AMDA core were synthesized and tested. The methoxy group was chosen a
general-purpose ‘probe’ functional group because of its synthetic flexibility, small size and
amphiphilic nature (i.e. it is able to participate in both polar and non-polar interactions). The
results of a systematic study of methoxy-substituted AMDA compounds, and the
concomitant effects that these substitutions have upon the compounds’ affinity for the
human 5-HT2A receptor are reported here.
Radioligand binding data (5-HT2A receptor affinities) were obtained for each of the target
compounds (Table 1). Within the methoxy-substituted AMDA series, the affinities varied by
correspondence: Richard B. Westkaemper, Department of Medicinal Chemistry, P. O. Box 980540, School of Pharmacy, Virginia
Commonwealth University, Richmond, VA 23298-0540, rbwestka@vcu.edu, Telephone: (804)828-6449, FAX: (804)828-7625.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 April 26.
Published in final edited form as:













more than 180-fold (4, Ki = 7.5 nM; 3, Ki = 1367 nM). Of all four positional isomers, only
3-methoxy-AMDA (4) showed increased affinity relative to the parent compound AMDA
(Ki = 20 nM). 4-Methoxy-AMDA (5, Ki = 124 nM) displayed a modest 6-fold decrease in
affinity compared to AMDA, while both 1- and 2-methoxy-AMDA (2, Ki = 1158 nM and 3,
Ki = 1367 nM, respectively) were found to have substantially reduced affinity (> 50-fold)
compared to AMDA.
Previous receptor modeling studies1 have identified two possible binding sites for 5-HT2A
ligands, as shown schematically in Figure 1. Site 1 is flanked primarily by transmembrane
helices TM3, TM5 and TM6, and has been proposed as the binding site for agonists,4, 5
partial agonists6 and antagonists.7, 8 Site 2 is an alternative binding site and is flanked by
TM1, TM2, TM3 and TM7. Ketanserin9, a prototypical 5-HT2A antagonist, and similar
butyrophenones10 have been proposed to simultaneously bind in both sites.
Each compound in Table 1 (with explicit consideration of stereoisomers) was docked into
two graphical receptor models representing the agonist-selected Site 1 and the antagonist-
selected Site 2 (see Experimental Methods). The overall quality of the docked poses was
determined using the ChemScore fitness function with visual inspection of the docked
solutions, and the top-ranking solution for each isomer was selected (see Supplemental
Table S1). In each case, GOLD was able to place the ligand into both Site 1 and Site 2.
However, productive hydrogen bonds were formed only for the more potent 3-methoxy-
AMDA ((R)-4 and (S)-4) and 4-methoxy-AMDA ((S)-5).11 For (R)-4, the methoxy oxygen
H-bonds with S1593.36, for (S)-4, the H-bond donor is S1312.61, and for (S)-5, H-bonding
occurs with S2395.43 (see Figure 2). In each of these solutions, the ammonium ion interacts
with D1553.32 and with other lipophilic/aromatic residues surrounding the AMDA core (see
Supplemental Table S2). The current models are consistent with earlier mutagenesis and
molecular modeling studies.12 The fact that both isomers of 4 are able to H-bond with the
receptor and both receive a relatively high ChemScore is consistent with its low Ki value.
Although there are several hydrogen bond donating sites within the agonist-selected Site 1
(S1593.36, T1603.37, S2395.43, S2425.46, W3366.48, N3436.55) and antagonist-selected Site 2
(S771.35, T811.39, S1312.61, W1513.28, S1593.36, S3737.46), our results suggest that 1-
methoxy AMDA (2) and 2-methoxy-AMDA (3) are not able to position themselves within
these sites in a way that allows the methoxy group to beneficially interact with them. This in
turn is consistent with the significantly reduced affinity of 2 and 3 for h5-HT2A. The binding
affinity of the methoxy-AMDA compounds can thus be directly correlated with their ability
to H-bond with residues in Site 1 or Site 2.
It should be noted that an alternative explanation for the reduced activity of 2 is the
possibility of internal H-bond formation. This would reduce the effectiveness of the amine
and the methoxy group to act as an H-bond donor and acceptor, respectively, and could
potentially impose a ligand conformation that reduces the complementarity of the ligand to
its binding site.
AMDA (1) was synthesized as previously described.3 The synthesis of 1-methoxy- (2) and
2-methoxy-9-aminomethyl-9,10-dihydroanthracene (3) (Scheme 1) was brought about by
the 1,4-addition of 2-[(methoxymethoxy)-methyl]phenylmagnesium bromide13 to the
nitrostyrenes 6a and 6b14 to give substituted 1,1-diaryl-2-nitroethanes 7a and 7b. The
MOM-protected benzyl alcohols 7a and 7b were deprotected using HCl to give the nitro
alcohols 8a and 8b, which were reduced to their respective amines to give amino alcohols
9a and 9b. Cyclodehydration of amino alcohols 9a and 9b using freshly prepared PPE in
CHCl3 gave the 1- and 2-methoxy substituted AMDAs 2 and 3 respectively. Synthesis of 3-
methoxy- (4) and 4-methoxy-9-aminomethyl-9,10-dihydroanthracenes (5) (Scheme 2) was
brought about by a standard Suzuki cross-coupling reaction between commercially available
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3-methoxybenzyl bromide 10a or 2-methoxybenzyl bromide 10b15 and 2-
formylphenylboronic acid to yield 2-(3-methoxybenzyl)benzaldehyde 11a and 2-(2-
methoxybenzyl)benzaldehyde 11b. Cyanosilylation of the aldehydes 11a and 11b using
TMSCN gave the corresponding cyano trimethylsilyl ethers 12a and 12b, which were
reduced with LiAlH4 to give the respective amino alcohols 13a and 13b. Cyclodehydration
of amino alcohols 13a and 13b using CH3SO3H and PPA respectively gave the 3-methoxy-
and 4-methoxy-substituted AMDAs 4 and 5.
The molecular modeling methodology used to generate the h5-HT2A receptor-ligand
complex models will be described briefly here, and is discussed in detail elsewhere.12 To
begin, the h5-HT2A receptor sequence was aligned using ClustalX 1.8316 with a profile of
several related class A GPCRs17 that included bovine rhodopsin. The result was an
unambiguous alignment (in the TM helical regions) of the h5-HT2A sequence with that of
bovine rhodopsin. Manual modifications were made to the alignment in the region of the
second extracellular loop to properly align the cysteine residues of the disulfide linkage.
This alignment, along with a file containing the atomic coordinates of bovine rhodopsin (‘A’
chain of PDB code 1U19), was used as input to the MODELLER software package18, 19 to
generate a population of 100 h5-HT2A homology models, each with a different
conformation. For the template rhodopsin structure, all residues within 12 Å of the bound
retinal ligand were mutated to alanine to encourage MODELLER to produce structurally
diverse receptor conformations. The N- and C-termini were truncated. The third intracellular
loop was modeled simply as a poly-Gly chain whose backbone coordinates were taken from
the structure of rhodopsin. Each receptor in the population was subsequently energy-
minimized without constraint in SYBYL 7.2 (Tripos Inc., St. Louis, MO) using the Tripos
Force Field (TFF) with Gasteiger-Hückel charges, a distance-dependent dielectric constant
of 4, a non-bonded interaction cutoff = 8 Å, and were terminated at an energy gradient of
0.05 kcal/(mol·Å). The automated docking program GOLD20, 21 version 3.01 (Cambridge
Crystallographic Data Centre, Cambridge, UK) was then used to dock a potent 5-HT2A
agonist (1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane; DOB) and a potent antagonist
(ketanserin) into each of the 100 receptor models. Based on the fitness scores and quality of
the docked poses, one receptor model was selected to represent the agonist binding site (Site
1 in Figure 1) and a second model was selected to represent an additional antagonist binding
site (Site 2 in Figure 1). After a small amount of conformational refinement and checks for
stereochemical integrity, the two receptor models were saved and used for subsequent
docking exercises.
Ligand molecules were sketched in using SYBYL and energy-minimized using the same
method and parameters as were used for the receptor models. Basic amines were protonated
to form ammonium ions. Ligand chirality was treated explicitly, with each isomer sketched,
energy-minimized and saved as a separate structure file. GOLD was then used to dock each
ligand structure into each of the two selected receptor models. The parameter set defined by
the “standard default settings” option was used in conjunction with a protein H-bond
constraint (default settings) that biased the docked solutions in favor of those in which the
ligand ammonium ion interacted with the conserved D1553.32. Ten genetic algorithm (GA)
runs were performed for each ligand at both Site 1 and Site 2. Short molecular dynamics
(MD) simulations were then carried out to enable the receptor-ligand complex to sample
alternative locally-accessible low-energy states in order to improve the binding free energy,
and to simultaneously increase the degree of receptor-ligand complementarity. The MD
simulations were run at 300K for 100 ps using the TFF with assigned Gasteiger-Hückel
charges, a distance-dependent dielectric constant = 4.0 and a non-bonded interaction cutoff
of 8.0 Å. To maintain the structural integrity of the receptor-ligand complexes during the
MD run, an aggregate was defined that constrained the atoms of all residues greater than 8.0
Å from the GOLD-docked solution to their starting coordinates. The receptor-ligand
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complexes were then subjected to a final energy minimization step using the same
parameters as shown above. All molecular modeling was performed on MIPS R14K- and
R16K-based IRIX 6.5 Silicon Graphics Fuel and Tezro workstations.
Binding assays and data analysis were performed through the NIMH Psychoactive Drug
Screening Program (PDSP). The 5HT2A competitive binding assay employs [3H]ketanserin
(a 5-HT2A antagonist) as the radioligand. Binding data were analyzed using Prism
(GraphPad Software, Inc., San Diego, CA). Details of the binding assay protocol may be
found at the PDSP home page, http://pdsp.med.unc.edu.
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Refer to Web version on PubMed Central for supplementary material.
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Schematic representation of sterically accessible binding sites (Site 1 and Site 2) within the
5-HT2A receptor.
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Proposed binding modes of the three MeO-AMDA isomers that exhibit substantial
hydrogen-binding interactions with residues within the binding crevice of the h5-HT2A
receptor. The receptor backbone for models representing Site 1 (agonist-selected) are
indicated with a green ribbon; those representing Site 2 (antagonist-selected) are indicated
with an orange ribbon. The sidechains of 5-HT2A residues within 5 Å of the ligand are
displayed as capped sticks and the ligand is rendered as a ball-and-stick model. a. (R)-3-
methoxy-AMDA ((R)-4) in Site 2. b. (S)-3-methoxy-AMDA ((S)-4) in Site 2. c. (S)-4-
methoxy-AMDA ((S)-5) in Site 1.
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Reagents and conditions: (a) 1-bromo-2-((methoxymethoxy)methyl)benzene, Mg, I2, THF,
65 → 0 °C, 12 h; (b) HCl, MeOH, 65 °C, 5 h; (c) H2, (50 psi), MeOH, 10% Pd/C, 25 °C, 36
h; (d) PPE, CHCl3, reflux, 3 h.
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Reagents and conditions: (a) 2-formylphenylboronic acid, Pd(PPh3)4, Na2CO3,
toluene:ethanol (9:1), 100 °C, 3 h; (b) TMSCN, ZnI2, CH2Cl2, 65 °C, 4 h; (c) LiAlH4, THF,
reflux, 12h; (d) CH3SO3H, 25 °C, 12h; PPA, 60 °C, 6 h.
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